Sosimerasib Sulfate Tablets (Jilemei)

Current understanding

To be populated as evidence accumulates.

Evidence log

• March 5, 2 — NMPA Approved Drugs List – February 2026 Update: Feb 2026: China’s NMPA granted priority review and conditional approval to Sosimerasib Sulfate Tablets (Jilemei) as first-line treatment for intermediate-2/high-risk PMF, post-PV MF, and post-ET MF (regulatory milestone; underlying trial data not detailed in source). (novelty: 4)

Open questions

Related